New Jersey Based Optimal Therapeutics Announces the Signing of Licensing Agreement for the Trademarked Ingredient Nextrutine(R) in Their Phosoplex Joint Formulation

CEDAR GROVE, NJ /Send2Press Newswire/ — New Jersey based Optimal Therapeutics announces the signings of licensing agreements for trademarked ingredients in their Phosoplex Joint Formulation. BioCell Collagen II from BioCell Technology LLC and Nextrutine(R) from Next Pharmaceutical are exciting ingredient additions to an already potent joint health formula.

Company spokesperson Camille Westhoff states: “Phosoplex with the addition of these two key ingredients puts Optima Therapeutics at the forefront of joint health and pain relief. It’s great to be associated with a product like Phosoplex because it can really change a person’s quality of life.”

Optimal Therapeutics also produces Fematril, Viastat, Zalestra, Zyroxin, Neurovar, Immunitril and other revolutionary lifestyle products.

Optimal Therapeutics products can be purchased online at or by way of Amazon.

News Source: Optimal Therapeutics :: This press release was issued by Send2Press® and is Copyright © 2005 Neotrope® News Network – all rights reserved.

Part of the Neotrope® News Network, USA.